A multi-centre trial of pollen-tyrosine adsorbate.
We report the results of a multi-centre trial involving 433 hay fever patients treated in 1975 with a 3-injection tyrosine-adsorbed vaccine containing glutaraldehyde-modified grass pollens and cultivated rye. Despite the high pollen counts recorded in Germany in 1975, treatment was considered to be effective in 73 per cent of the patients, irrespective of their age, sex or past history. Side effects were normally mild although the incidence of local reactions was relatively high. Only six patients discontinued treatment due to untoward reactions and there were no cases of anaphylactic shock. This paper adds further evidence to support the view that this vaccine offers a safe, effective and convenient method of treatment for grass pollen allergy.
D000293:Adolescent; D000328:Adult; D000936:Antigen-Antibody Complex / Q000627:therapeutic use*; D001249:Asthma / Q000188:drug therapy; D002648:Child; D003888:Desensitization, Immunologic; D005260:Female; D006801:Humans; D007164:Immunosorbents / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D011058:Pollen; D006255:Rhinitis, Allergic, Seasonal / Q000188:drug therapy; D014443:Tyrosine / Q000276:immunology*
D000936:Antigen-Antibody Complex; D007164:Immunosorbents; D014443:Tyrosine